Results

1–10 of 23 results for Pegcetacoplan

Impact of AREDS Oral Micronutrient Supplementation on Geographic Atrophy Progression: Insights From thePhase 3 OAKS and DERBY Trials
Paul Hahn, MD, PhD, FASRS
Annual Meeting Talks
2025
Progression of Geographic Atrophy in Patients Receiving Both Anti-VEGF and Pegcetacoplan Injections
Sean David Adrean, MD, FAAO, FASRS
Annual Meeting Talks
2025
A Descriptive Analysis of Patients Who Received Pegcetacoplan and Anti-VEGF for the Treatment ofGeographic Atrophy and Neovascular AMD
Nimesh A. Patel, MD
Annual Meeting Talks
2025
Clinical Utility of the Fellow Eye in Patients With Bilateral GA Due to AMD: Long-Term Data from thePegcetacoplan Clinical Program
Diana V Do, MD, FASRS
Annual Meeting Talks
2025
Early vs Delayed Pegcetacoplan Treatment for GA Secondary to AMD: 48-Month Results From OAKS, DERBY,and GALE Open-Label Extension
Roger A. Goldberg, MD, MBA
Annual Meeting Talks
2025
Baseline Characteristics Associated With Geographic Atrophy Progression in the OAKS and DERBY Trials
Srinivas Reddy Sadda, MD
Annual Meeting Talks
2025
Pegcetacoplan Versus Avacincaptad pegol: Efficacy of Treatment in the Same Eye
Josh Wallsh
Updates from the Field
2026
Exudative Age-Related Macular Degeneration Events from the OAKS and DERBY Clinical Trials of Pegcetacoplan in Geographic Atrophy
Roger A. Goldberg, MD, MBA
Annual Meeting Talks
2023
Pegcetacoplan vs Avacincaptad Pegol in Patients With Geographic Atrophy: An Anchored Matching-Adjusted Indirect Comparison of the Phase 3 Trials
Paul Hahn, MD, PhD, FASRS
Annual Meeting Talks
2023
Retinal Tissue Preservation With Intravitreal Pegcetacoplan in Patients With Geographic Atrophy
Sunir J. Garg, MD, FACS, FASRS
Annual Meeting Talks
2023